Patients who have ANCA-associated vasculitis (AAV) with renal involvement have high short-term overall rates of renal and patient survival, according to findings from a Swedish study presented at the 60th European Renal Association Congress in Milan, Italy.
Ylva Östlund, MD, of Sahlgrenska University Hospital in Göteborg, Sweden, and colleagues studied 91 patients diagnosed with AAV with renal involvement from March 1, 2002 to October 30, 2018 at a single center. Of these, 52 (57%) were diagnosed with proteinase 3 (PR3)-ANCA and 39 (43%) with myeloperoxidase (MPO)-ANCA. Both groups received comparable induction therapy, but a significantly higher proportion of patients with PR3-ANCA than MPO-ANCA received plasma exchange therapy (44% vs 21%).
The overall 1- and 5-year renal survival rates were 91% and 69%, respectively, with no significant differences between the PR3-ANCA and MPO-ANCA groups, the investigators reported in a poster presentation. The overall 1- and 5-year patient survival rates were 92% and 77%, respectively. The mean survival time was 11.5 years overall.
Treatment with plasma exchange had no effect on 1-year renal and patient survival among patients with an estimated glomerular filtration rate below 15 mL/min/1.73 m2, according to the investigators.
Cox regression analysis revealed that older age significantly predicted a higher mortality risk and MPO-ANCA subtype significantly predicted a lower mortality risk, Dr Östlund’s team reported.
Östlund Y, Saeed A, Mihovilovic K. Patient outcomes in a Swedish single-centre cohort of ANCA-associated vasculitis with renal involvement. Presented at: ERA 2023, June 15-18, Milan, Italy. Abstract 5679.
This article originally appeared on Renal and Urology News